New Drug Approvals

Home » 2013 » June (Page 4)

Monthly Archives: June 2013

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,809,870 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Saudi MERS outbreak showed SARS-like features, including possible superspreader


Free webinars on chronic pain and opioid use


PalDaily's avatarAll Things Palliative - Article Feed

The American Medical Association (AMA) is hosting two free webinars on chronic pain and opioid use later this month.

via Free webinars on chronic pain and opioid use.

View original post

Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients


PalDaily's avatarAll Things Palliative - Article Feed

Medical care in Japan is distinguished by the ability for patients to access both Western and Kampo medical cares at the same time. There is a high degree of trust in the safety of Kampo therapies because they are practiced by medical doctors who are educated with fundamental diagnosis of Western medicine. Highly reliable clinical studies are being published, demonstrating that palliative or supportive care for cancer patients using Kampo preparations alleviates adverse effects of chemotherapy or radiotherapy.

via Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients.

View original post

ALMIRALL-Product development pipeline


Almirall - Solutions with you in mind

 

Preclin. Phase I Phase II Phase III Registr. Registration application
Respiratory Autoimmune Dermatology Gastrointestinal
LAS190792 MABA >2014
Aclidinium bromide Antimuscarinic Approved by the FDA & EMA
AB + Formoterol (LAS40464) Antimuscarinic + LABA Undisclosed
Abediterol (LAS100977) + ICS OD LABA + ICS >2014
LAS186323 DHODH inhibitor Undisclosed
Sativex® CB agonist Undisclosed
LAS189913 S1P1 Undisclosed
LAS41002 Topical anti-inflamatory Registration application in EU
LAS41004 Combination 2014
LAS41008 Psoriaris Undisclosed
Linaclotide Guanylate cyclase type-C agonist Approved by the EMA

AB: Aclidinium Bromide | ICS: Inhaled Corticoesteroid | RA: Reumatoid Artritis | MS: Multiple Sclerosis
IBS-C: Irritable Bowel Syndrome with associated Constipation

http://www.almirall.com/webcorp2/cda/ImD_03_02.jsp?langSuscripcion=3

Amgen In Focus


Amgen In Focus
Seeking Alpha
According to Amgen, they have 45 drugs in development from Phase 1 to Phase 3. Conversely, Gilead has 32 drugs in development and Pfizer has 64. Meanwhile, Gilead only has 8 drugs in Phase 3, Pfizer has 25, and Amgen has 14. 7 of those Phase 3 

http://seekingalpha.com/article/1510002-amgen-in-focus?source=google_news

Amgen has the second deepest pipeline of drugs of the three large cap biotechs. According to Amgen, they have 45 drugs in development from Phase 1 to Phase 3. Conversely, Gilead has 32 drugs in development and Pfizer has 64. Meanwhile, Gilead only has 8 drugs in Phase 3, Pfizer has 25, and Amgen has 14. 7 of those Phase 3 drugs are focused on cancer treatments for Amgen, more than either Pfizer or Gilead. Keep in mind that 12.4 million people learn they have cancer each year, while 7.6 million people lose that battle each year. The CDC predicts that the global number of cancer related deaths will increase by 80% by 2030. It doesn’t take a rocket scientist to know that cancer treating drugs presents the largest opportunity for any drug maker considering those statistics. Amgen has the inside track versus Gilead and Pfizer as far as quantity of drugs in late stage development.

Pipeline
This information is current as of February 11, 2013. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

 

Phase 1
Cancer Immunotherapy
Various cancer types
AMG 110 is an anti-EpCAM (epithelial cell adhesion molecule) x anti-CD3 (BiTE®) bispecific antibody. It is being investigated as a cancer treatment.
Antibody
Inflammatory diseases
AMG 139 is a human monoclonal antibody. It is being investigated as a treatment for Crohn’s disease. AMG 139 is being jointly developed in collaboration with AstraZeneca.
Antibody
Asthma
AMG 157 is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated as a treatment for asthma. AMG 157 is being jointly developed in collaboration with AstraZeneca.
Antibody
Bone-related conditions
AMG 167 is a humanized monoclonal antibody that inhibits the action of sclerostin. AMG 167 is being developed in collaboration with UCB for bone-related conditions.
Other
Modality
Various cancer types
AMG 172 is a human anti-CD27L antibody drug conjugate. It is being investigated as a cancer treatment.
Oral/Small Molecule
Various cancer types
AMG 208 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment.
Oral/Small Molecule
Various cancer types
AMG 232 is a small molecule. It is being investigated as a cancer treatment.
Oral/Small Molecule
Hematologic malignancies
AMG 319 is a small molecule inhibitor of PI3 Kinase delta. It is being investigated as a cancer treatment.
Antibody
Migraine
AMG 334 is a human monoclonal antibody that inhibits the receptor for Calcitonin Gene-Related Peptide (CGRP). It is being investigated for the prevention of migraine.
Oral/Small Molecule
Various cancer types
AMG 337 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment.
Oral/Small Molecule
Autoimmune diseases
AMG 357 is a small molecule. It is being investigated as a treatment for autoimmune diseases.
Antibody
Systemic lupus erythematosus
AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca.
Other
Modality
Glioblastoma
AMG 595 is a human anti-EGFRvIII (epidermal growth factor receptor) antibody drug conjugate. It is being investigated as a treatment for glioblastoma.
Antibody
Autoimmune diseases
AMG 729 is a humanized monoclonal antibody that targets CD19 and CD32b to inhibit B cell. It is being investigated as a treatment for systemic lupus erythematosus and rheumatoid arthritis.
Antibody
Various cancer types
AMG 780 is a human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Antibody
Systemic lupus erythematosus
AMG 811 is a human monoclonal antibody that inhibits interferon gamma. It is being investigated as a treatment for systemic lupus erythematosus.
Antibody
Various cancer types
AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor associated macrophage (TAM) function. It is being investigated as a cancer treatment.
Protein/Peptibody
Type 2 diabetes
AMG 876 is a fusion protein. It is being investigated as a treatment for type 2 diabetes.
Oral/Small Molecule
Various cancer types
AMG 900 is a small molecule inhibitor of Aurora kinases A, B, and C. It is being investigated as a cancer treatment.

Phase 2
Oral/Small Molecule
Type 2 diabetes
AMG 151 is a small molecule glucokinase activator. It is being investigated as a treatment for type 2 diabetes.
Antibody
Inflammatory bowel disease
AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative colitis and Crohn’s disease. AMG 181 is being jointly developed in collaboration with AstraZeneca.
Other
Modality
Secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis
AMG 416 is a peptide agonist of the human cell surface calcium-sensing receptor (CaSR). It is being investigated as a treatment for secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis.
Oral/Small Molecule
Schizophrenia
AMG 747 is a small molecule inhibitor of glycine transporter type-1 (GlyT-1). It is being investigated as a treatment for negative symptoms and cognitive deficits associated with schizophrenia.
Cancer Immunotherapy
Acute lymphoblastic leukemia
Blinatumumab is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody. It is being investigated as a cancer treatment.
Cancer Immunotherapy
Non-Hodgkin’s Lymphoma
Blinatumumab is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody. It is being investigated as a cancer treatment.
Antibody
Inflammatory diseases
Brodalumab is a human monoclonal antibody that inhibits the interleukin-17 receptor. It is being investigated as a treatment for a variety of inflammatory diseases. Brodalumab is being jointly developed in collaboration with AstraZeneca.
Oral/Small Molecule
Heart failure
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. It is being investigated for the treatment of heart failure. We are developing this product in collaboration with Cytokinetics, Inc.
Antibody
Rheumatoid arthritis
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Protein/Peptibody
Various cancer types
Trebananib is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Antibody
Squamous cell head and neck cancer
Vectibix® is a human monoclonal antibody antagonist of the epidermal growth factor receptor (EGFr) pathway. It is being investigated as a cancer treatment.
Antibody
Giant cell tumor of the bone
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Antibody
Hypercalcemia of malignancy
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
 

Phase 3
Antibody
Hyperlipidemia
AMG 145 is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). It is being investigated as a treatment for hyperlipidemia.
Protein/Peptibody
Myelodysplastic syndromes
Aranesp® is a recombinant human protein agonist of the erythropoietin receptor.
Brodalumab is a human monoclonal antibody that inhibits the interleukin-17 receptor. It is being investigated as a treatment for a variety of inflammatory diseases. Brodalumab is being jointly developed in collaboration with AstraZeneca.
Antibody
Glucocorticoid-induced osteoporosis
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Antibody
Male osteoporosis (EU)
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Antibody
Gastric cancer
Rilotumumab is a human monoclonal antibody that inhibits the action of hepatocyte growth factor/scatter factor. It is being investigated as a cancer treatment.
Antibody
Postmenopausal osteoporosis
Romosozumab is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being developed in collaboration with UCB for the treatment of postmenopausal osteoporosis.
Sensipar®/Mimpara® is an orally-administered small molecule that lowers parathyroid hormone (PTH) levels in blood by increasing sensitivity of the calcium-sensing receptor (CaSR) to extracellular calcium. It is being evaluated in post renal transplant patients.
Talimogene laherparepvec is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a cancer treatment.
Protein/Peptibody
Ovarian cancer
Trebananib is a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.
Antibody
First- and second-line colorectal cancer (U.S.)
Vectibix® is a human monoclonal antibody antagonist of the epidermal growth factor receptor (EGFr) pathway. It is being investigated as a cancer treatment.
Antibody
Cancer-related bone damage (skeletal-related events) in patients with multiple myeloma
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Antibody
Delay or prevention of bone metastases in breast cancer
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
Antibody
Delay or prevention of bone metastases in prostate cancer (EU)
Denosumab is a human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK) which is a key mediator of osteoclast formation, function, and survival. It is being investigated across a range of conditions including osteoporosis, treatment-induced bone loss, rheumatoid arthritis and numerous tumor types across the spectrum of cancer-related bone diseases, including hypercalcemia of malignancy.
 
Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

Tocilizumab Impresses in Polyarticular Juvenile Arthritis


tocilizumab

Tocilizumab Impresses in Polyarticular Juvenile Arthritis
Medscape

MADRID, Spain — Children with polyarticular juvenile idiopathic arthritis treated with tocilizumab (Actemra, Genentech) achieved high response rates with sustained improvement in the phase 3 CHERISH trial.

The results prompted the US Food and Drug Administration toapprove tocilizumab for this indication. The drug is already approved for systemic juvenile idiopathic arthritis and for adults with moderate to severe rheumatoid arthritis.

read all at

http://www.medscape.com/viewarticle/806572

Tocilizumab (INN, or atlizumab, developed by Hoffmann–La Roche and Chugai and sold under the trade names Actemra and RoActemra) is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of RA in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such asautoimmune diseasesmultiple myeloma and prostate cancer.

HISTORY OF HOMEOPATHY


The theories and principles of homeopathy have their origins in medicinal traditions established thousands of years ago in Ancient Greece and Rome.

In the 5th century BCE the Greek physician Hippocrates (460–377 BCE) clearly established the idea that disease was the result of natural forces rather than divine intervention, and that patients’ own powers of healing should be encouraged (see page 19). Contemporary medical theories were based upon the Law of Contraries, which advocated treating an illness by prescribing a substance that produced opposite or contrary symptoms. Diarrhea, for example, could be treated by a substance that caused constipation, such as aluminum hydroxide.
In contrast, Hippocrates developed the use of the Law of Similars, based on the principle that “like cures like” (see page 18). This theory proposed that substances capable of causing symptoms of illness in healthy people could also be used to treat similar symptoms during illness. For example, Veratrum album (white hellebore), which was considered effective against cholera, caused violent purging that led to severe dehydration if administered in large doses—symptoms exactly like those of cholera itself. Between the 1st and 5th centuries CE the Romans made further developments in medicine. They introduced more herbs into the pharmacopeias, improved public hygiene, and observed the structure and function of the human body, although this was limited by social taboo, which prevented the dissection of bodies. Existing medical knowledge was codified and rationalized by Galen (130–200 CE), a Roman physician, anatomist, and physiologist.
He adopted many ancient Greek principles, including the Aristotelian theory o the “four humors,” which claimed that the human body was made up of four humors—blood, choler (yellow bile), melancholy (black bile), and phlegm— that must be kept in balance to ensure vitality and health.
After the decline of the Roman empire, little progress was made for centuries in the field of European medicine. A combination of herbal folklore, religious influences, and Galenic theory provided the basis for understanding and treating illness right through to the 17th century. Only when the Swiss physician and alchemist Paracelsus (1493–1541) began to develop his theories did the study of medicine start to evolve again. Paracelsus revived the ancient Greek theory of the Doctrine of Signatures, which was based on the premise that the external appearance of a plant—God’s “signature”—indicated the nature of its healing properties. For example, Chelidonium majus (greater celandine) was used to treat conditions affecting the liver and gallbladder because the yellow juice of the plant resembled bile.
Paracelsus argued that disease was linked to external factors such as contaminated food and water rather than to mystical forces, and he challenged his contemporaries to recognize the body’s natural ability to heal itself, claiming that the practice of medicine should be based on detailed observation and “profound knowledge of nature and her works.” According to his theories, all plants and metals contained active ingredients that could be prescribed to match specific illnesses. Concentrating on practical experiments rather than on alchemy, he laid the foundations for the early stages of chemistry and subsequent development of pharmaceutical medicine, introducing new medicines, such as opium, sulfur, iron, and arsenic, into the contemporary repertory. His exploration of the chemical and medicinal properties of many substances, and his advocacy of the Hippocratic concept of “like cures like,” also made Paracelsus a key figure in the development of homeopathy.
According to the British homeopath James Compton Bunett (1840–1901), the author of several important works on homeopathy that are still in use today, “Paracelsus planted the acorn from which the mighty oak of homeopathy has grown.” intellectual climate encouraged important developments in the study of medicine, including the isolation of active ingredients from herbs, such as the extraction of morphine from the opium poppy in 1803. It was in 1790, while translating A Treatise on Materia Medica by a Scottish teacher, physician, and chemist, Dr. William Cullen, that Hahnemann began an investigation which was to prove paramount to the subsequent development of homeopathy. In his treatise Cullen argued that quinine, when isolated from Cinchona officinalis (see page 49), was a good treatment for malaria because it was an stringent. Hahnemann knew that other, more powerful, astringents had no such effect on malaria.
He dosed himself with quinine, recording the results and effectively beginning the first “proving”  see page 22). Although he did not have malaria, he found that he began to develop symptoms of the disease one after the other. With each dose of quinine, the symptoms recurred and lasted for several hours, but if he stopped taking quinine his symptoms began to disappear. Hahnemann went on to test quinine on other people, noting their reactions in great detail. The test subjects were not allowed to eat or drink strong foods such as spices, alcohol, or coffee, which he felt might distort the results. He repeated the proving process on other substances that were in use as medicines, such as arsenic and belladonna, and used the results to build up a “symptom picture” of each remedy’s effects (see page 23).
After conducting provings for six years, Hahnemann extended his research to the sick. Prior to prescription, he gave his patients a thorough physical examination and noted any existing symptoms. He questioned them closely regarding their lifestyles, general health, outlook on life, and other factors that made them feel better or worse. Following the principle of like cures like, Hahnemann then matched individual symptoms as closely as possible to the symptom picture of a remedy, and prescribed accordingly.

Development & definition

Hahnemann’s work gradually brought about the establishment of new type of medicine. In 1796 he published his first book on the subject, entitled A New Principle for Ascertaining the Curative Powers of Drugs and Some Examinations of Previous Principles. He called his new system “homeopathy,” from the Greek homeo meaning “similar” and pathos meaning “suffering.” In 1810 he set out its principles in The Organon of Rationale Medicine, and two years later he began teaching homeopathy at the University of Leipzig. During the course of his lifetime, Hahnemann proved about 100 remedies, and also continued to develop and refine the theory and practice of the system (see page 18).
The medical establishment remained generally very sceptical of Hahnemann’s theories, and he in turn continued to be intensely critical of conventional medical practice. He became known as the “raging hurricane” due to his furious tirades and sarcastic critiques during lectures at Leipzig. He also antagonized contemporary pharmacists by giving only one medicine at a time, which was contrary to their (highly lucrative) practice of generally prescribing expensive mixtures of several remedies. During the 19th century, homeopathy spread rapidly across Europe to Asia and the Americas. In the US, Dr. Constantine Hering (1800–80) and Dr. James Tyler Kent (1849–1916) were responsible for popularizing the therapy and introducing new ideas and practices (see page 19). By the time of Hahnemann’s death in 1843, homeopathy was firmly established in many parts of the world, although there remained antagonism and distrust between the advocates of conventional medicine and those of homeopathy.
Between 1860 and 1890 homeopathy flourished, as many homeopathic hospitals and schools were opened, and many new remedies were proved, considerably enlarging the materia medica. Hahnemann’s followers were often doctors who defected from conventional medicine after personally experiencing treatment, including an English doctor, Frederick Quin (1799–1878), who was cured of cholera by the Camphora remedy. Quin first visited Hahnemann in Germany in 1826, and went on to introduce homeopathy in the UK, founding the first homeopathic hospital in London in 1849. During a cholera outbreak in 1854, the mortality rate at his hospital was less than half that of conventional hospitals. This information was suppressed by the national Board of Health on the grounds that “the figures would give sanction to a practice opposed to the maintenance of truth and the progress of science,” illustrating the close stranglehold the medical establishment had achieved within social institutions.

Decline & resurrection


The predominance of conventional medicine was echoed in the US. By the late 19th century, homeopathy had become a significant part of US medical practice, with about 15 percent of doctors being practicing  homeopathy. During the early 20th century, however, homeopathy became largely overshadowed by conventional medicine, principally due to the rise of the American Medical Association.
The British Medical Association played a similar role in the UK, and divisions within homeopathy began to weaken the force of its message still further. Strict followers of Hahnemann and Kent’s original theories followed “classical” or “Kentian” constitutional prescribing, believing that a person’s emotional characteristics and physical symptoms should be taken into account and favoring high potencies (see page 19). Led by the British homeopath Dr. Richard Hughes (1836–1902), one strand of practitioners had, however, begun to prescribe on pathological symptoms alone, favoring low doses. This unfortunate division in homeopathic practice enabled the conventional medical establishment to gain the upper hand, and by the 1920s homeopathy had been largely suppressed in the UK.
During the late 20th century there has been a resurgence in the popularity of homeopathy, possibly due to disenchantment with aspects of conventional medicine. In many countries, particularly in central Europe, its popularity never waned to the same extent as in the UK and US, although differences in practice have evolved. Single-remedy classical prescribing is prevalent worldwide, although in Germany and France complex homeopathy or polypharmacy (the use of combination remedies or several remedies) is also popular (see page 21). In Australia there is a strong link with naturopathy, with homeopathic remedies often incorporated into naturopathic practice. In India, homeopaths have long worked successfully alongside traditional Ayurvedic medicine and conventional medicine. In the 1990s, courses in Eastern Europe pioneered by British teachers revitalized interest in homeopathy, and in Russia it continues to be implemented and developed. In South America, homeopathy is widely taught in medical schools, while in the US it is undergoing a major resurgence of popularity. According to a 1998 survey of Americans and their health, over
6 million Americans had used homeopathy in the preceding 12 months. Noting that it had been integrated into the national healthcare systems of numerous countries, including Germany, the United Kingdom, India, Pakistan, Sri Lanka, and Mexico, the World Health Organization is publishing a position paper in 2006.

Let’s Set a Global Drug Quality Benchmark by Kiran M Shaw, Biocon


See on Scoop.itNew drug approvals

With Indian-made generics accounting for a US market share of over 25 per cent, it is not surprising that it is gaining significant mindshare of the Food and Drug Administration ( FDA). The spate o…

See on newdrugapprovals.wordpress.com

Let’s Set a Global Drug Quality Benchmark by Kiran M Shaw, Biocon


Kiran Mazumdar Shaw

With Indian-made generics accounting for a US market share of over 25 per cent, it is not surprising that it is gaining significant mindshare of the Food and Drug Administration ( FDA). The spate of quality issues with leading Indian pharmaceutical companies in the past couple of years however should not be viewed in isolation. Big Pharma in the West, too, has been facing increasing flak from the FDA and other regulators over good manufacturing practice ( GMP) violations. High profile names like J& J, Genzyme (Sanofi), GSK, Sandoz, Watson, Teva and many others have encountered their share of quality problems and have been served with ‘warning letters’ from FDA

http://kiranmazumdarshaw.blogspot.in/2013/06/lets-set-global-drug-quality-benchmark.html

READ ALL AT THE LINK ABOVE

Adamas claims success with new and improved Parkinson’s drug


See on Scoop.itNew drug approvals

amantadine Adamas claims success with new and improved Parkinson’s drug Adamas Pharmaceuticals is claiming success with a Phase II/III study of its extended-release version of amantadine for Parkin…

See on newdrugapprovals.wordpress.com